Zongertinib

宗艾替尼

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameZongertinib
Drug Alias Name宗格替尼HERNEXEOS圣赫途BI-1810631
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsEsophageal adenocarcinomaMetastatic breast cancerGastroesophageal Junction Neoplasms +[10] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2025/08/08
Country/TerritoryBelgiumCanadaUnited States +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgSino Biopharmaceutical LtdNippon Boehringer Ingelheim Co Ltd +[9] 
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaMetastatic breast cancerGastroesophageal Junction Neoplasms +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A